SPA
ADMA icon

Sherbrooke Park Advisers’s ADMA Biologics ADMA Stock Holding History

Sherbrooke Park Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,063
Closed -$183K – 505
2025
Q2 		$183K Buy
+10,063
New +$205K 0.08% 405
2025
Q1 		– Sell
-20,066
Closed -$344K – 575
2024
Q4 		$344K Buy
20,066
+6,117
+44% +$115K 0.11% 339
2024
Q3 		$279K Buy
13,949
+1,680
+14% +$26.1K 0.06% 601
2024
Q2 		$137K Sell
12,269
-43,035
-78% -$361K 0.02% 804
2024
Q1 		$365K Buy
55,304
+41,357
+297% +$226K 0.07% 486
2023
Q4 		$63K Sell
13,947
-23,997
-63% -$88.8K 0.03% 429
2023
Q3 		$136K Buy
+37,944
New +$146K 0.04% 432

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sherbrooke Park Advisers's ADMA Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 10,063 shares — an estimated $183K sold.

Sherbrooke Park Advisers first reported a position in ADMA in Q3 2023 and held it in 7 quarters. The position peaked at $365K in Q1 2024. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 10,063 ADMA Biologics shares in Q3 2025, an estimated $183K.
  • Sherbrooke Park Advisers first reported a position in ADMA Biologics in Q3 2023 and held it in 7 quarters.
  • Sherbrooke Park Advisers's ADMA Biologics position peaked at $365K in Q1 2024.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.